215 related articles for article (PubMed ID: 16990639)
1. Prevention of cytomegalovirus disease in solid organ transplant patients: prophylactic versus preemptive therapy.
Baillie GM
Am J Health Syst Pharm; 2006 Oct; 63(19 Suppl 5):S10-6. PubMed ID: 16990639
[TBL] [Abstract][Full Text] [Related]
2. Can preemptive cytomegalovirus monitoring be as effective as universal prophylaxis when implemented as the standard of care in patients at moderate risk?
McGillicuddy JW; Weimert NA; Taber DJ; Turner A; Mitchell LA; Wray DW; Egidi MF; Kuppachi S; Hughes MG; Baliga PK; Chavin KD
Transplantation; 2010 May; 89(10):1218-23. PubMed ID: 20410854
[TBL] [Abstract][Full Text] [Related]
3. [Cytomegalovirus infection after solid-organ transplantation, its risk factors, direct and indirect effects and prevention strategies].
Varga M; Remport A; Czebe K; Péter A; Toronyi E; Sárváry E; Fehérvári I; Sulyok B; Járay J
Orv Hetil; 2008 Mar; 149(12):551-8. PubMed ID: 18343771
[TBL] [Abstract][Full Text] [Related]
4. Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients.
Singh N
Clin Infect Dis; 2001 Mar; 32(5):742-51. PubMed ID: 11229841
[TBL] [Abstract][Full Text] [Related]
5. Antiviral dosing and efficacy for prophylaxis of cytomegalovirus disease in solid organ transplant recipients.
Cochrane AB
Am J Health Syst Pharm; 2006 Oct; 63(19 Suppl 5):S17-21. PubMed ID: 16990640
[TBL] [Abstract][Full Text] [Related]
6. Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients.
Torres-Madriz G; Boucher HW
Clin Infect Dis; 2008 Sep; 47(5):702-11. PubMed ID: 18652557
[TBL] [Abstract][Full Text] [Related]
7. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.
Hodson EM; Ladhani M; Webster AC; Strippoli GF; Craig JC
Cochrane Database Syst Rev; 2013 Feb; (2):CD003774. PubMed ID: 23450543
[TBL] [Abstract][Full Text] [Related]
8. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
Witzke O; Hauser IA; Bartels M; Wolf G; Wolters H; Nitschke M;
Transplantation; 2012 Jan; 93(1):61-8. PubMed ID: 22094954
[TBL] [Abstract][Full Text] [Related]
9. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.
Hodson EM; Barclay PG; Craig JC; Jones C; Kable K; Strippoli GF; Vimalachandra D; Webster AC
Cochrane Database Syst Rev; 2005 Oct; (4):CD003774. PubMed ID: 16235341
[TBL] [Abstract][Full Text] [Related]
10. Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients.
Len O; Gavaldà J; Aguado JM; Borrell N; Cervera C; Cisneros JM; Cuervas-Mons V; Gurguí M; Martin-Dávila P; Montejo M; Muñoz P; Bou G; Carratalà J; Torre-Cisneros J; Pahissa A;
Clin Infect Dis; 2008 Jan; 46(1):20-7. PubMed ID: 18171208
[TBL] [Abstract][Full Text] [Related]
11. Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance.
van der Beek MT; Berger SP; Vossen AC; van der Blij-de Brouwer CS; Press RR; de Fijter JW; Claas EC; Kroes AC
Transplantation; 2010 Feb; 89(3):320-6. PubMed ID: 20145523
[TBL] [Abstract][Full Text] [Related]
12. Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy.
Kalil AC; Freifeld AG; Lyden ER; Stoner JA
PLoS One; 2009; 4(5):e5512. PubMed ID: 19436751
[TBL] [Abstract][Full Text] [Related]
13. Impact of valganciclovir prophylaxis on the development of severe late-cytomegalovirus disease in high-risk solid organ transplant recipients.
Cervera C; Pineda M; Linares L; Marcos MA; Esteva C; Antón A; Cofán F; Ricart MJ; Navasa M; Pérez-Villa F; Pumarola T; Moreno A
Transplant Proc; 2007 Sep; 39(7):2228-30. PubMed ID: 17889146
[TBL] [Abstract][Full Text] [Related]
14. Antiviral drugs for cytomegalovirus in transplant recipients: advantages of preemptive therapy.
Singh N
Rev Med Virol; 2006; 16(5):281-7. PubMed ID: 16878336
[TBL] [Abstract][Full Text] [Related]
15. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.
Hodson EM; Craig JC; Strippoli GF; Webster AC
Cochrane Database Syst Rev; 2008 Apr; (2):CD003774. PubMed ID: 18425894
[TBL] [Abstract][Full Text] [Related]
16. Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients.
Bodro M; Sabé N; Lladó L; Baliellas C; Niubó J; Castellote J; Fabregat J; Rafecas A; Carratalà J
Liver Transpl; 2012 Sep; 18(9):1093-9. PubMed ID: 22532316
[TBL] [Abstract][Full Text] [Related]
17. Formulary considerations for drugs used to prevent cytomegalovirus disease.
Pescovitz MD
Am J Health Syst Pharm; 2003 Dec; 60(23 Suppl 8):S17-21. PubMed ID: 14686231
[TBL] [Abstract][Full Text] [Related]
18. Anti-cytomegalovirus prophylaxis in solid-organ transplant recipients.
Falagas ME; Vardakas KZ
Clin Microbiol Infect; 2006 Jul; 12(7):603-5. PubMed ID: 16774555
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients.
Kalil AC; Levitsky J; Lyden E; Stoner J; Freifeld AG
Ann Intern Med; 2005 Dec; 143(12):870-80. PubMed ID: 16365468
[TBL] [Abstract][Full Text] [Related]
20. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients.
Khoury JA; Storch GA; Bohl DL; Schuessler RM; Torrence SM; Lockwood M; Gaudreault-Keener M; Koch MJ; Miller BW; Hardinger KL; Schnitzler MA; Brennan DC
Am J Transplant; 2006 Sep; 6(9):2134-43. PubMed ID: 16780548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
